Clinical trials
Observational Atherosclerosis trials in Russia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
11 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2018 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 5 |
| Unknown status | 3 |
| Recruiting | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| I.M. Sechenov First Moscow State Medical University | 2 |
| Bayer | 1 |
| Center for Strategic Planning, of the Federal Medical and Biological Agency | 1 |
| Central Clinical Hospital of the Russian Academy of Sciences | 1 |
| Eurasian Association of Therapists | 1 |
| Institute for Atherosclerosis Research, Russia | 1 |
| Novartis Pharmaceuticals | 1 |
| Russian Cardiology Research and Production Center | 1 |
| Ryazan State Medical University | 1 |
| St. Petersburg State Pavlov Medical University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Atherosclerosis | 11 |
| Cardiovascular Diseases | 4 |
| Coronary Artery Disease | 4 |
| Stroke | 2 |
| Acquired Immunodeficiency Syndrome | 1 |
| Acute Coronary Syndrome | 1 |
| Angina Pectoris | 1 |
| Angina, Stable | 1 |
| Atrial Fibrillation | 1 |
| Carotid Artery Diseases | 1 |
Trials
Showing 1 to 11 of 11. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.